Several phase 3 trials demonstrated improved OS for melanoma, NSCLC, and renal cell carcinoma patients treated with PD1-blocking antibodies,33–38 resulting in Food and Drug Administration (FDA) approval of two PD1 inhibitors as second-line therapies for patients with these malignancies. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.